Clinical Trials Logo

Clinical Trial Summary

This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B-NHL patients.


Clinical Trial Description

This is a single-arm, open label, phase I study to evaluate the safety and preliminary efficacy of C-CAR039 in adults with relapsed/refractory B-cell Non-Hodgkin's Lymphoma. 10 patients are planned to be enrolled. Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of C-CAR039. Following manufacture of the drug product, subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide prior to C-CAR039 infusion. All subjects who have received C-CAR039 infusion will be followed for up to 24 months ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04696432
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Active, not recruiting
Phase Phase 1
Start date November 27, 2020
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04317885 - A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects Phase 1
Terminated NCT02361346 - Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL Phase 1/Phase 2
Active, not recruiting NCT04693676 - A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma Phase 1
Recruiting NCT04655677 - A Study of EXP039 Treatment in Subjects With r/r NHL Subjects Phase 1
Suspended NCT04148742 - Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) Phase 1/Phase 2
Active, not recruiting NCT03000192 - HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
No longer available NCT02715843 - Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma